OGEN · Oragenics Inc.
What's happening
- OGEN is down 1.35% today, trading at $0.43. — Live quote
- It's trading within 3% of its 52-week low ($0.41). (Finnhub fundamentals)
- Volume today (100) is well below its 3-month average of 31,290. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.51 actual vs. $-3.06 estimated (+50.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.6M | $2.4M | $2.1M | $2.8M | $3.8M |
| P/E | -0.26 | -0.25 | -0.21 | -0.31 | -0.40 |
| Price/Book | 0.71 | 0.39 | 0.21 | -1.33 | 27.75 |
| ROE | -274.30% | -157.83% | -101.90% | 435.07% | -6853.02% |
| ROA | -183.31% | -130.27% | -78.85% | -432.63% | -243.87% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -19750.0%. Finnhub fundamentals ↗
- Trailing 52-week price return is -67.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OGEN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.6M | -$2.3M | -$3.1M | -$1.7M | -$2.0M | -$2.4M | -$2.3M | -$2.5M |
| Net income | -$2.5M | -$2.2M | -$3.1M | -$2.3M | -$2.2M | -$2.5M | -$2.3M | -$2.5M |
| EPS (diluted) | $-0.57 | $-0.51 | $-1.96 | $-3.10 | $-3.65 | $-11.32 | $-15.27 | $-0.70 |
| EPS (basic) | $-0.57 | $-0.51 | $-1.96 | $-3.10 | $-3.65 | $-11.32 | $-15.27 | $-0.70 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.5M | $7.5M | $10.1M | $12.7M | $2.1M | $3.9M | $1.5M | $5.2M |
| Total liabilities | $1.8M | $1.3M | $1.8M | $2.9M | $4.3M | $3.7M | $1.7M | $2.1M |
| Stockholders' equity | $3.7M | $6.2M | $8.3M | $9.8M | -$2.1M | $137.7K | -$211.9K | $3.1M |
| Total current assets | $5.5M | $7.5M | $10.1M | $12.7M | $2.1M | $3.9M | $1.5M | $4.1M |
| Total current liabilities | — | — | — | — | — | — | — | — |
| Cash & equivalents | $3.9M | $6.1M | $4.4M | $11.4M | $2.0M | $3.4M | $864.8K | $3.1M |
| Marketable securities (current) | — | — | $4.0M | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | — | — | — | — | — | $202.8K | $65.7K |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $4.5K | $4.4K | $4.3K | $4.1K | $823 | $21.5K | $419 | $9.4K |
| Retained earnings | -$231.4M | -$228.8M | -$226.6M | -$224.3M | -$221.3M | -$219.0M | -$216.8M | -$213.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.2M | -$2.2M | -$2.8M | -$3.0M | -$1.3M | -$2.1M | -$2.0M | -$2.0M |
| Investing cash flow | $0 | $4.0M | — | — | — | — | — | — |
| Financing cash flow | -$56.1K | -$92.0K | -$168.6K | $12.4M | -$133.0K | $4.7M | -$260.9K | $3.8M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $17.6K | $17.4K | $611.8K | $6.0K | $6.8K | $17.7K | $57.7K | $330.8K |
| Deferred income taxes | — | — | — | — | — | — | -$1.4M | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | $0 | $0 | $0 | $2.2M | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | $37.7K | $131.5K | $87.0K |
| Gross profit | — | — | — | — | — |
| Operating income | -$9.4M | -$10.6M | -$20.9M | -$14.4M | -$15.8M |
| Net income | -$9.8M | -$10.6M | -$20.7M | -$14.3M | -$15.7M |
| EPS (diluted) | $-4.56 | $-47.88 | $-9.18 | $-7.11 | — |
| EPS (basic) | $-4.56 | $-47.88 | $-9.18 | $-7.11 | $-8.09 |
| Operating margin | — | — | -$55.5K | -$11.0K | -$18.1K |
| Net margin | — | — | -$54.9K | -$10.9K | -$18.1K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $10.1M | $1.5M | $5.0M | $14.8M | $28.2M |
| Total liabilities | $1.8M | $1.7M | $1.8M | — | — |
| Stockholders' equity | $8.3M | -$211.9K | $3.2M | $13.0M | $26.5M |
| Total current assets | $10.1M | $1.5M | $3.9M | $14.3M | $27.7M |
| Total current liabilities | — | — | $1.8M | $1.6M | $1.4M |
| Cash & equivalents | $4.4M | $864.8K | $3.5M | $11.4M | $27.3M |
| Marketable securities (current) | $4.0M | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, plant & equipment | — | — | $0 | $121.1K | $45.7K |
| Accrued liabilities | — | $202.8K | $222.7K | $812.9K | — |
| Deferred revenue (current) | — | — | — | — | — |
| Common stock & paid-in capital | $4.3K | $419 | $3.1K | $2.0K | $2.0K |
| Retained earnings | -$226.6M | -$216.8M | -$206.2M | -$185.6M | -$171.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.2M | -$8.6M | -$7.3M | -$15.2M | -$13.5M |
| Investing cash flow | — | — | -$936.3K | -$115.5K | -$43.9K |
| Financing cash flow | $16.8M | $6.0M | $283.9K | -$494.9K | $23.1M |
| Free cash flow | — | — | — | -$15.4M | -$13.5M |
| Capital expenditures | — | — | — | $127.5K | $43.9K |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $642.4K | $516.0K | $1.0M | $742.2K | $1.7M |
| Deferred income taxes | — | -$1.4M | -$5.8M | -$3.7M | $870.9K |
| Change in accounts receivable | — | — | — | — | — |
| Change in inventory | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | $2.2M | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OGEN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-11-30 to 2025-12-12
Recent transactions
- Most recent: Telling Fred (Director) — Open market sale of 210 shares on 2025-12-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Telling Fred | Director | Open market sale | 2025-12-12 | 210 |
| Odyssey Health, Inc. | 10% owner | Open market sale | 2025-06-18 | 5,044 |
| KOSKI ROBERT C | Director | Derivative conversion | 2024-12-11 | 5,000 |
| DUNTON ALAN W | Director | Open market sale | 2024-12-06 | 66 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-12-12 | Telling Fred | Director | Open market sale | 210 | $0.94 |
| 2025-06-18 | Odyssey Health, Inc. | 10% owner | Open market sale | 5,044 | $4.26 |
| 2025-06-17 | Odyssey Health, Inc. | 10% owner | Open market sale | 2,000 | $4.46 |
| 2025-06-16 | Odyssey Health, Inc. | 10% owner | Open market sale | 5,000 | $4.45 |
| 2025-06-13 | Odyssey Health, Inc. | 10% owner | Open market sale | 5,000 | $4.27 |
| 2024-12-11 | KOSKI ROBERT C | Director | Derivative conversion | 5,000 | — |
| 2024-12-06 | DUNTON ALAN W | Director | Open market sale | 66 | $0.36 |
| 2024-12-06 | Telling Fred | Director | Open market sale | 3,597 | $0.36 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-16 | 8-K | 2026-09-16 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-06 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-05-19 | 8-K | 2026-05-18 | View on SEC.gov → |
| 2026-05-08 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
| 2026-04-13 | 8-K | 2026-04-13 | View on SEC.gov → |
| 2026-03-31 | 8-K | 2026-03-27 | View on SEC.gov → |
| 2026-03-16 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-11 | 8-K | 2026-03-10 | View on SEC.gov → |
Recent news
Headlines about OGEN (Oragenics Inc.). Links open the publisher — we don’t host full articles.
-
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 2026-10-09 -
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
Yahoo Finance · 2026-09-16 -
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Yahoo Finance · 2026-08-28 -
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
Yahoo Finance · 2026-07-07 -
Sidoti Events, LLC's May Micro-Cap Virtual Conference
Yahoo Finance · 2026-05-20 -
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
Yahoo Finance · 2026-05-19 -
Oragenics reports Q1 results
Seeking Alpha · 2026-05-18 -
ORAGENICS PROVIDES INVESTOR UPDATE
Yahoo Finance · 2026-05-18
No headlines in this category right now — try “All”.